Titan Pharmaceuticals (TTNP) Competitors $3.64 -0.13 (-3.32%) Closing price 04/17/2025 03:51 PM EasternExtended Trading$3.72 +0.09 (+2.48%) As of 04/17/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock TTNP vs. NRSN, CLDI, SLGL, MEIP, COCP, SYBX, IPA, QNTM, MTVA, and IMNNShould you be buying Titan Pharmaceuticals stock or one of its competitors? The main competitors of Titan Pharmaceuticals include NeuroSense Therapeutics (NRSN), Calidi Biotherapeutics (CLDI), Sol-Gel Technologies (SLGL), MEI Pharma (MEIP), Cocrystal Pharma (COCP), Synlogic (SYBX), ImmunoPrecise Antibodies (IPA), Quantum Biopharma (QNTM), MetaVia (MTVA), and Imunon (IMNN). These companies are all part of the "pharmaceutical products" industry. Titan Pharmaceuticals vs. NeuroSense Therapeutics Calidi Biotherapeutics Sol-Gel Technologies MEI Pharma Cocrystal Pharma Synlogic ImmunoPrecise Antibodies Quantum Biopharma MetaVia Imunon NeuroSense Therapeutics (NASDAQ:NRSN) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment. Does the MarketBeat Community believe in NRSN or TTNP? Titan Pharmaceuticals received 333 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. However, 66.67% of users gave NeuroSense Therapeutics an outperform vote while only 53.17% of users gave Titan Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNeuroSense TherapeuticsOutperform Votes266.67% Underperform Votes133.33% Titan PharmaceuticalsOutperform Votes33553.17% Underperform Votes29546.83% Do insiders and institutionals hold more shares of NRSN or TTNP? 1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Comparatively, 24.9% of Titan Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, NRSN or TTNP? NeuroSense Therapeutics has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Is NRSN or TTNP more profitable? NeuroSense Therapeutics' return on equity of 0.00% beat Titan Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NeuroSense TherapeuticsN/A N/A -590.79% Titan Pharmaceuticals N/A -118.01%-103.79% Does the media favor NRSN or TTNP? In the previous week, Titan Pharmaceuticals had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 2 mentions for Titan Pharmaceuticals and 1 mentions for NeuroSense Therapeutics. Titan Pharmaceuticals' average media sentiment score of 0.99 beat NeuroSense Therapeutics' score of -1.00 indicating that Titan Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment NeuroSense Therapeutics Negative Titan Pharmaceuticals Positive Do analysts prefer NRSN or TTNP? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Titan Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation & earnings, NRSN or TTNP? Titan Pharmaceuticals has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Titan Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroSense TherapeuticsN/AN/A-$11.28M-$0.54-1.91Titan Pharmaceuticals$180K18.46-$5.57M-$5.21-0.70 SummaryTitan Pharmaceuticals beats NeuroSense Therapeutics on 8 of the 14 factors compared between the two stocks. Get Titan Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TTNP vs. The Competition Export to ExcelMetricTitan PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.32M$2.84B$5.31B$7.35BDividend YieldN/A1.86%5.45%4.29%P/E Ratio-0.7030.4821.9417.82Price / Sales18.46441.91380.9597.68Price / CashN/A168.6838.2634.64Price / Book0.413.466.453.98Net Income-$5.57M-$72.06M$3.22B$247.81M1 Month Performance2.83%-16.76%-9.76%-7.91%1 Year Performance-50.34%-26.05%11.49%1.53% Titan Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TTNPTitan Pharmaceuticals1.2849 of 5 stars$3.64-3.3%N/A-48.8%$3.32M$180,000.00-0.7010Analyst ForecastShort Interest ↓News CoverageNRSNNeuroSense Therapeutics0.371 of 5 stars$0.97-2.0%N/A-32.0%$13.26MN/A-1.5210Short Interest ↑CLDICalidi Biotherapeutics2.2897 of 5 stars$0.50flat$15.00+2,923.6%N/A$13.13M$50,000.000.0038News CoverageGap UpSLGLSol-Gel Technologies1.9864 of 5 stars$0.47+0.9%$5.00+963.8%-41.8%$13.09M$11.71M-1.3850News CoverageGap UpMEIPMEI Pharma2.2353 of 5 stars$1.93-3.5%$7.00+262.7%-39.4%$12.86M$65.30M-0.34100Analyst ForecastShort Interest ↓Gap DownCOCPCocrystal Pharma1.9851 of 5 stars$1.26-11.3%$7.00+455.6%-10.5%$12.82MN/A-0.6810Gap DownSYBXSynlogicN/A$1.08flatN/A-42.1%$12.63M$8,000.00-0.2680IPAImmunoPrecise Antibodies2.6969 of 5 stars$0.40+12.3%$4.00+889.6%-64.7%$12.56M$24.00M-0.5280Short Interest ↓Gap DownQNTMQuantum BiopharmaN/A$6.36-10.0%N/AN/A$12.21MN/A-0.41N/AMTVAMetaVia2.0439 of 5 stars$1.40-4.0%$12.00+756.5%N/A$12.13MN/A0.0010Analyst ForecastNews CoveragePositive NewsGap UpHigh Trading VolumeIMNNImunon1.6238 of 5 stars$0.83-13.9%$21.50+2,501.3%-20.9%$12.08M$500,000.00-0.4430Short Interest ↑Negative News Related Companies and Tools Related Companies NeuroSense Therapeutics Alternatives Calidi Biotherapeutics Alternatives Sol-Gel Technologies Alternatives MEI Pharma Alternatives Cocrystal Pharma Alternatives Synlogic Alternatives ImmunoPrecise Antibodies Alternatives Quantum Biopharma Alternatives MetaVia Alternatives Imunon Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TTNP) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Titan Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
